source
- FDA approves Infilbray, first therapy for neurological symptoms of Type 3 Gaucher diseaseThe U.S. Food and Drug Administration has approved Infilbray (venglustat) tablets for treating the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15…
- Marrow Therapeutics raises $173M to develop simpler alternative to gene therapies for sickle cell and beta thalassemiaMarrow Therapeutics, a newly announced biotech startup, has secured $173 million in venture funding to pursue a new treatment for severe blood disorders such as sickle cell disease and beta thalass…BioPharma Dive · 1d agoDealPositive